EVÄVAARA-DESIGN
11.5.2021 12:48:07 CEST | Business Wire | Press release
Remote working has raised a number of challenges that have been taken up by Finnish pioneering designer of functional furniture, Evävaara Design. Evävaara is launching two completely new workstation designs to fit any home: the larger, mobile sshhh 3 and the smaller sshhh 7 . The workstations support the wellbeing of employees with good ergonomic and acoustic design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005612/en/
Antti Evävaara, founder and chief designer of Evävaara Design, has almost twenty years’ experience in designing and producing functional furniture, with solid expertise in good acoustics and user comfort, which provide the basis for their workstation design.
“In today’s world we are constantly surrounded by irritants and noise that can make it hard to focus on something. Our products aim to create a quiet, personal space that allows you to focus”, says Evävaara .
The furniture-shaped workstations designed by Evävaara are a response to the challenges posed by the increase in remote working. According to remote work and virtual leadership expert Ulla Vikman of Timanttia Consulting, those who do a great deal of remote work, often experience interruptions and are sometimes challenged by a blurred line between work and free time.
“Someone who does a great deal of remote work would be distracted if the necessary tools, such as displays and paperwork, are constantly on all over their home. By intruding your thoughts constantly, these things tend to increase stress levels and focusing becomes more difficult”, says Vikman .
The design of Evävaara workstations is focused on a number of details that support concentration and ergonomics. The wood and felt of the workstation muffles both external and internal noise and improves the acoustics of the whole room. Standard equipment for the workstation includes
- Power sockets and cords
- USB port
- LED lights
- Storage pockets for paperwork and other materials
The larger sshhh3 can be purchased with an additional, adjustable chair. After work, the workstation doors are simply closed and the workstation becomes a mobile cabinet. A neutral colour scheme makes the unit blend seamlessly in any home environment.
In order to boost the efficiency of your working day, Evävaara Design workstations are easy to deploy. The workstation is delivered assembled and ready to use. Evävaara Design workstations are available direct from the designer.
Today the products of Evävaara Design are in use all over Europe wherever a calm space is required, for instance in open plan offices and libraries. They have also garnered some international interest since Vincent Gregoire, Nelly Rodi’s creative director and a celebrity in the business, included Evävaara products in a video showcasing new trends at the Maison & Objet fair in February.
More information: https://www.evavaaradesign.com/etatyopisteet/
Evavaara Design is a Finnish pioneer in functional furniture design in Europe – creating quiet corners for every environment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005612/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom